- Home
- HY vs TSHA Comparison
HY vs TSHA Comparison
Compare HY & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HY
- TSHA
- Stock Information
- Founded
- HY 1991
- TSHA 2019
- Country
- HY United States
- TSHA United States
- Employees
- HY N/A
- TSHA N/A
- Industry
- HY Construction/Ag Equipment/Trucks
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- HY Industrials
- TSHA Health Care
- Exchange
- HY Nasdaq
- TSHA Nasdaq
- Market Cap
- HY 710.8M
- TSHA 728.4M
- IPO Year
- HY N/A
- TSHA 2020
- Fundamental
- Price
- HY $41.73
- TSHA $2.35
- Analyst Decision
- HY Strong Buy
- TSHA Strong Buy
- Analyst Count
- HY 1
- TSHA 5
- Target Price
- HY $70.00
- TSHA $8.20
- AVG Volume (30 Days)
- HY 59.2K
- TSHA 3.4M
- Earning Date
- HY 08-05-2025
- TSHA 08-11-2025
- Dividend Yield
- HY 3.46%
- TSHA N/A
- EPS Growth
- HY N/A
- TSHA N/A
- EPS
- HY 5.60
- TSHA N/A
- Revenue
- HY $4,162,100,000.00
- TSHA $7,224,000.00
- Revenue This Year
- HY N/A
- TSHA N/A
- Revenue Next Year
- HY $2.55
- TSHA N/A
- P/E Ratio
- HY $7.43
- TSHA N/A
- Revenue Growth
- HY N/A
- TSHA N/A
- 52 Week Low
- HY $34.13
- TSHA $1.05
- 52 Week High
- HY $84.44
- TSHA $3.31
- Technical
- Relative Strength Index (RSI)
- HY 55.90
- TSHA 43.76
- Support Level
- HY $38.82
- TSHA $2.25
- Resistance Level
- HY $42.97
- TSHA $2.51
- Average True Range (ATR)
- HY 1.15
- TSHA 0.15
- MACD
- HY 0.32
- TSHA -0.03
- Stochastic Oscillator
- HY 75.42
- TSHA 24.39
About HY Hyster-Yale Materials Handling Inc.
Hyster Yale Inc designs, engineers, manufactures, sells and services a comprehensive line of lift trucks, attachments, aftermarket parts and technology solutions marketed globally under the Hyster and Yale brand names. The Company has five segments, which include three in the lift truck business as discussed below, as well as Bolzoni S.p.A. (Bolzoni) and Nuvera Fuel Cells, LLC (Nuvera). Majority of revenue is from Lift Trucks. geographically operates in America, EMEA, JAPIC, maximum revenue from America.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.